The Penn State team's analysis of TCGA data across thousands of tumors reveals EXO1 overexpression in 20-30% of breast, ovarian, and other malignancies, driving replication-fork degradation and single-strand gap expansion that mimics BRCA-deficient genomic instability. This observational cohort study, while large-scale, lacks randomization and relies on bulk RNA-seq correlations rather than functional validation in every sample. Laboratory follow-up used commercial cell lines with forced EXO1 overexpression, confirming toxic double-strand breaks via both wild-type and catalytically dead constructs—an in vitro design that cannot capture tumor microenvironment effects or patient pharmacokinetics. Prior work in Nature Communications (2021) on EXO1 in BRCA contexts and a 2023 Cell Reports study on fork protection mechanisms together indicate that EXO1-high cells are selectively sensitive to PARP inhibitors and platinum agents even without BRCA mutations, a connection the original coverage under-emphasized. No conflicts of interest were disclosed. If validated in prospective trials, EXO1 testing could reclassify a substantial fraction of HR-proficient tumors as treatable with existing targeted regimens, addressing resistance patterns missed by BRCA-centric models.